Renato Lenzi, M.D.

Peer-Reviewed Articles

1. Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 15(11):1791-1799, 2017. e-Pub 2017. PMID: 28579181.
2. Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA, National Comprehensive Cancer Network. Occult primary, version 3.2014. J Natl Compr Canc Netw 12(7):996-74, 2014. PMID: 24994917.
3. Carlson H, Lenzi R, Raber MN, Varadhachary GR. A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary. Int J Clin Oncol 18(2):226-31, 2013. e-Pub 2012. PMID: 22218909.
4. McHenry M, Parker PA, Baile WF, Lenzi R. Voice analysis during bad news discussion in oncology: reduced pitch, decreased speaking rate and nonverbal communication of empathy. Support Care Cancer 20(5):1073-8, 2012. e-Pub 2011. PMID: 21573770.
5. Ettinger DS, Agulnik M, Cates JM, Cristea M, Denlinger CS, Eaton KD, Fidias PM, Gierada D, Gockerman JP, Handorf CR, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Shulman LN, Smerage JB, Varadhachary GR, Zager JS, Zhen WK, National Comprehensive Cancer Network. Occult primary. J Natl Compr Canc Netw 9(12):1358-95, 2011. PMID: 22157556.
6. Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res 17(12):4063-70, 2011. e-Pub 2011. PMID: 21531815.
7. Lenzi R, Baile WF, Costantini A, Grassi L, Parker PA. Communication training in oncology: results of intensive communication workshops for Italian oncologists. Eur J Cancer Care (Engl) 10.1111(2):2354-60, 2011. PMID: 20477861.
8. Costantini A, Baile WF, Lenzi R, Costantini M, Ziparo V, Marchetti P, Grassi L. Overcoming cultural barriers to giving bad news: feasibility of training to promote truth-telling to cancer patients. J Cancer Educ 24(3):180-5, 2009. PMID: 19526404.
9. Ettinger DS, Agulnik M, Cristea M, Eaton K, Fidias PM, Gockerman JP, Hameed O, Handorf C, Harris EI, Jacobs CD, Javle M, Khushalani NI, Kvols L, Lenzi R, Lewis NL, Rashid A, Saltz L, Shulman LN, Zager JS, Zhen W. Occult primary. J Natl Compr Canc Netw 6(10):1026-60, 2008. PMID: 19176200.
10. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26(27):4442-8, 2008. PMID: 18802157.
11. Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 26(21):3496-502, 2008. PMID: 18640930.
12. Hassan MM, Bondy ML, Wolff RA, Abbruzzese JL, Vauthey JN, Pisters PW, Evans DB, Khan R, Chou TH, Lenzi R, Jiao L, Li D. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 102(12):2696-707, 2007. e-Pub 2007. PMID: 17764494.
13. Hassan MM, Abbruzzese JL, Bondy ML, Wolff RA, Vauthey JN, Pisters PW, Evans DB, Khan R, Lenzi R, Jiao L, Li D. Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study. Cancer 109(12):2547-56, 2007. PMID: 17492688.
14. Lenzi R, Edwards R, June C, Seiden MV, Garcia ME, Rosenblum M, Freedman RS. Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma. J Transl Med 5:66, 2007. PMID: 18076766.
15. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer 106(7):1624-33, 2006. PMID: 16518827.
16. Li D, Jiao L, Li Y, Doll MA, Hein DW, Bondy ML, Evans DB, Wolff RA, Lenzi R, Pisters PW, Abbruzzese JL, Hassan MM. Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis 27(1):103-11, 2006. e-Pub 2005. PMID: 15987714.
17. Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 55(6):559-64, 2005. e-Pub 2005. PMID: 15726370.
18. Li D, Ahmed M, Li Y, Jiao L, Chou TH, Wolff RA, Lenzi R, Evans DB, Bondy ML, Pisters PW, Abbruzzese JL, Hassan MM. 5,10-Methylenetetrahydrofolate reductase polymorphisms and the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 14(6):1470-6, 2005. PMID: 15941958.
19. Ettinger DS, Arnoletti JP, Gockerman JP, Handorf C, Havlin KA, Jacobs CD, Javle M, Kvols L, Lenzi R, Rashid A, Rhoades CA, Ridge JA, Saltz L, Shulman LN, Sondak VK, Thompson JA, Twardowski P, Zhen W, National Comprehensive Cancer Network. Occult primary cancer clinical practice guidelines. J Natl Compr Canc Netw 3(2):214-33, 2005. PMID: 19817031.
20. Lenzi R, Baile WF, Berek J, Back A, Buckman R, Cohen L, Parker PA. Design, conduct and evaluation of a communication course for oncology fellows. J Cancer Educ 20(3):143-9, 2005. PMID: 16122361.
21. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 101(3):466-75, 2004. PMID: 15274059.
22. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100(11):2292-9, 2004. PMID: 15160331.
23. Varadhachary GR, Abbruzzese JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer 100(9):1776-85, 2004. PMID: 15112256.
24. Weinbergh JS, Suki D, Hanbali F, Cohen ZR, Lenzi R, Sawaya R. Metastasis of esophageal carcinoma to the brain. Cancer 98(9):1925-33, 2003.
25. Cohen L, Baile WF, Henninger E, Agarwal SK, Kudelka AP, Lenzi R, Sterner J, Marshall GD. Physiological and psychological effects of delivering medical news using a simulated physician-patient scenario. J Behav Med 26(5):459-71, 2003. PMID: 14593853.
26. Tempero AM, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21(18):3402-8, 2003.
27. Melichar B, Lenzi R, Rosenblum M, Kudelka AP, Kavanagh JJ, Melicharova K, Templin S, Garcia ME, Abbruzzese JL, Freedman RS. Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. J Immunother 26(3):270-6, 2003.
28. Pentz RD, Lenzi R, Holmes F, Khan MM, Verschraegen C. Discussion of the do-not-resuscitate order: a pilot study of perceptions of patients with refractory cancer. Support Care Cancer 10(8):573-8, 2002. e-Pub 2002. PMID: 12436216.
29. Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies. Clin Cance rREs 8(12):3686-95, 2002.
30. Pisters PW, Wolff RA, Janjan NA, Cleary KR, Charnsangavej C, Crane CN, Lenzi R, Vauthey JN, Lee JE, Abbruzzese JL, Evans DB. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 20(10):2537-44, 2002. PMID: 12011133.
31. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong AB, Phan T, Nguyen Q, Janjan NA. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?. Int J Radiat Oncol Biol Phys 52(5):1293-302, 2002. PMID: 11955742.
32. Baile WF, Lenzi R, Parker PA, Buckman R, Cohen L. Oncologists' attitudes toward and practices in giving bad news: an exploratory study. J Clin Oncol 20(8):2189-96, 2002. PMID: 11956281.
33. Lenzi R, Yalcin S, Evans DB, Abbruzzese JL. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 20(4):464-72, 2002. PMID: 12094541.
34. Crane CH, Wolff RA, Abbruzzese JL, Evans DB, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Lahoti S, Vauthey JN, Janjan NA. Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. Semin Oncol 28(3 Suppl 10):25-33, 2001. PMID: 11510031.
35. Parker PA, Baile WF, de Moor C, Lenzi R, Kudelka AP, Cohen L. Breaking bad news about cancer: patients' preferences for communication. J Clin Oncol 19(7):2049-56, 2001. PMID: 11283138.
36. Janjan NA, Crane C, Feig BW, Cleary K, Dubrow R, Curley S, Vauthey JN, Lynch P, Ellis LM, Wolff R, Lenzi R, Abbruzzese J, Pazdur R, Hoff PM, Allen P, Brown T, Skibber J. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24(2):107-12, 2001. PMID: 11319280.
37. Crane CH, Janjan NA, Abbruzzese JL, Curley S, Vauthey J, Sawaf HB, Dubrow R, Allen P, Ellis LM, Hoff P, Wolff RA, Lenzi R, Brown TD, Lynch P, Cleary K, Rich TA, Skibber J. Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. Int J Radiat Oncol Biol Phys 49(1):107-16, 2001. PMID: 11163503.
38. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29(1):9-18, 2001. PMID: 11560155.
39. Crane CH, Antolak JA, Rosen II, Forster KM, Evans DB, Janjan NA, Charnsangavej C, Pisters PW, Lenzi R, Papagikos MA, Wolff RA. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30(3):123-32, 2001. PMID: 12540024.
40. Crane C, Janjan N, Evans D, Wolff R, Ballo M, Milas L, Mason K, Charnsangavej C, Pisters P, Lee J, Lenzi R, Vauthey J, Wong A, Phan T, Nguyen Q, Abbruzzese J. Toxicity and Efficacy of Concurrent Gemcitabine and Radiotherapy for Locally Advanced Pancreatic Cancer. Int J Gastrointest Cancer 29(1):9-18, 2001. PMID: 12754400.
41. Janjan NA, Breslin T, Lenzi R, Rich TA, Skibber J. Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil. J Pain Symptom Manage 20(4):266-72, 2000. PMID: 11027908.
42. Janjan NA, Crane CN, Feig BW, Cleary K, Dubrow R, Curley SA, Ellis LM, Vauthey J, Lenzi R, Lynch P, Wolff R, Brown T, Pazdur R, Abbruzzese J, Hoff PM, Allen P, Brown B, Skibber J. Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 47(3):713-8, 2000. PMID: 10837955.
43. Pisters PW, Hudec WA, Lee JE, Raijman I, Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, Abbruzzese JL, Evans DB. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 18(4):860-7, 2000. PMID: 10673529.
44. Wolff RA, Chiao P, Lenzi R, Pisters PW, Lee JE, Janjan NA, Crane CH, Evans DB, Abbruzzese JL. Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs 18(1):43-56, 2000. PMID: 10830140.
45. Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES-A six-step protocol for delivering bad news: application to the patient with cancer. Oncologist 5(4):302-11, 2000. PMID: 10964998.
46. Baile WF, Kudelka AP, Beale EA, Glober GA, Myers EG, Greisinger AJ, Bast RC, Goldstein MG, Novack D, Lenzi R. Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer 86(5):887-97, 1999. PMID: 10463990.
47. Baile WF, Glober GA, Lenzi R, Beale EA, Kudelka AP. Discussing disease progression and end-of-life decisions. Oncology (Williston Park) 13(7):1021-31; discussion 1031-6, 1038, 1999. PMID: 10442349.
48. Pisters PW, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16(12):3843-50, 1998. PMID: 9850029.
49. Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage 16(3):171-8, 1998. PMID: 9769619.
50. Ayoub JP, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver. J Clin Oncol 16(6):2105-12, 1998. PMID: 9626210.
51. Freedman RS, Lenzi R, Kudelka AP, Lawrence DD, Rosenblum M, Platsoucas CD. Intraperitoneal immunotherapy of peritoneal carcinomatosis. Cytokines Cell Mol Ther 4(2):121-40, 1998. PMID: 9681251.
52. Lenzi R, Kim EE, Raber MN, Abbruzzese JL. Detection of primary breast cancer presenting as metastatic carcinoma of unknown primary origin by 111In-pentetreotide scan. Ann Oncol 9(2):213-6, 1998. PMID: 9553668.
53. Evans DB, Lee JE, Pisters PW, Charnsangavej C, Ellis LM, Chiao PJ, Lenzi R, Abbruzzese JL. Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. Cancer Treat Res 90:109-25, 1997. PMID: 9367080.
54. Baile WF, Lenzi R, Kudelka AP, Maguire P, Novack D, Goldstein M, Myers EG, Bast RC. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ 12(3):166-73, 1997. PMID: 9376255.
55. Abbruzzese JL, Abbruzzese MC, Lenzi R, Raber MN, Hess KR. Are time or intensity factors important to the definition of metastases of unknown origin?. J Natl Cancer Inst 88(7):462-3, 1996. PMID: 8618241.
56. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13(8):2094-103, 1995. PMID: 7636553.
57. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12(6):1272-80, 1994. PMID: 8201389.
58. Abbruzzese JL, Lenzi R, Raber MN, Pathak S, Frost P. The biology of unknown primary tumors. Semin Oncol 20(3):238-43, 1993. PMID: 8503019.
59. Lenzi R, Liu MH, Tarsetti F, Slott PA, Alpini G, Zhai WR, Paronetto F, Lenzen R, Tavoloni N. Histogenesis of bile duct-like cells proliferating during ethionine hepatocarcinogenesis. Evidence for a biliary epthelial nature of oval cells. Lab Invest 66(3):390-402, 1992.
60. Lenzi R, Alpini G, Liu MH, Rand JH, Tavoloni N. von Willebrand factor antigen is not an accurate marker of rat and guinea pig liver endothelial cells. Liver 10(6):372-9, 1990.
61. Alpini G, Lenzi R, Zhai WR, Slott PA, Liu MH, Sarkozi L, Tavolini N. Bile secretory function of intrahepatic biliary epithelium in in the rat. Am J Physiol 257(1 Pt 1):124-33, 1989.

Manuals, Teaching Aids, Other Teaching Publications

1. Lin EH, Burton A, Lenzi R, Espirito J, Anthony L, Karp D. Cancer Matrix Manual. Advanced Medical Publishing, Inc: Madison, Wisconsin, 2006.

Abstracts

1. Nizar Bhulani, Lianchun Xiao, Manal Hassan, Renato Lenzi;. Predictors of no-show among international patients with cancer: A 4-year analysis. J Clin Oncol 35, 2017.
2. 11. Botrus G, Shalaby AS, Kaseb AO, Lenzi R, Abdel-Wahab R, Wolff RA, Hassan M. The protective effect of hormonal intake on risk of hepatocellular carcinoma in the United States. J Clin Oncol 33(suppl), 2015.
3. Raghav KPS, Mhadgut H, Lei X, Overman MJ, Lenzi R, Raber MN, Varadhachary G. Cancer of unknown pirmary in adolescents and young adults: clinicopathologic features, prognostic factors, and survival outcomes. J Clin Oncol 32(5S), 2014.
4. Lenzi R, Coleman M, Xiao L, Abdel-Wahab R, Hassan M. Retrospective study to evaluate variables predicting no-show international patients. J Clin Oncol 32(Suppl), 2014.
5. Stemke Hale K, Wang HW, Karanth S, Raber MN, Carlson HR, Lenzi R, Abbruzzese JL, Mills GB, Varadhachary GR. Mutation profling in patients with carcinoma of unknown primary using the Sequenom MassARRAY system. J Clin Oncol Suppl, 2012.
6. Varadhachary GR, Siddharth K, Hainsworth JD, Wang H, Carlson HR, Lenzi R, Abbruzzese JL, Raber MN, Greco FA. Patients with carcinoma of unknown primary and "colon cancer profile": Cllinicopathologic features and survival data. Proc Am Soc Clin Onc, 2012.
7. Lenzi R, Parker PA, Baile WF, McHenry M. Voice analysis during bad news discussion in oncology: decreased speaking rate, pitch, and nonverbal communication of empathy. J Clin Oncol 29(Suppl), 2011.
8. Carlson HR, Karanth S, Zarzour MA, Lenzi R, Raber MN, Varadhachary GR. Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: clinicopathologic features and survival data. J Clin Oncol 29(Suppl), 2011.
9. Varadhachary GR, Edmonston TB, Karanth S, Carlson HR, Lebanony D, Rosenwald S, Lenzi R, Spector Y, Cohen D, Raber MN. Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in patients with cancer of unknown primary site (CUP). ASCO Annual Meeting Proceedings 28(15S), 2010.
10. Parker PA, Baile W, Cohen I, Abbruzzese J, Varadhachary G, Ho L, LaPushin T, Dayao P, Lenzi R. Illness uncertainty, sense of coherence, and psychosocial adjustment in patients with pancreatic cancer. Annals of Behavioral Medicine 37S:51, 2009.
11. Lenzi R, Rashid A, Ordonez N, Raber MN, Varadhachary GR, Erlander M, Abbruzzese JL. Gene profiling validation of molecular markers in patients with cancer of unknown pirmary (CUP). ASCO Annual Meeting Proceedings 25(18S):21130, 2007.
12. Varadhachary GR, Talanov D, Jatkoe T, Rashid A, Lenzi R, Chadha R, Baden J, Wang Y, Abbruzzese JL, Raber MN. Prospective study of a 10-gene molecular assay to predict tissue of origin in patients with carcinomas of unknown primary (CUP). ASCO Annual Meeting Proceedings 25(18S):21096, 2007.
13. Rashid A, Hess KR Lenzi R, Raber MN, Abbruzzese JL, Varadhachary GR. Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP). ASCO Annual Meeting Proceedings 23(16S):9683, 2005.
14. Varadhachary GR, Blais JC, Raber MN, Lenzi R, Hoff PM, Abbruzzese JL. Phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine (GEMOX) in cancer of unknown primary (CUP). ASCO Annual Proceedings 23(16S):4140, 2005.
15. Parker PA, Lenzi R, Cohen L, Berek J, Back A, Buckman R, Baile WF. Evaluation of an interactive communication skills workshop for oncology fellows. Psycho-Oncology 12(4):S171, 2003.
16. Xiong H, Du M, Wolff R, Lenzi R, Dumas P, Lassere Y, Plunkett W, Abbruzzese J. Parmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Proc Am Soc Clin Onc, 2002.
17. Wolff RA, Evans DB, Gravel DM, Lenzi R, Pisters PW, Lee JE, Janjan NA, Charnsangavej C, Abbruzzese JL. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7(8):2246-53, 2001. PMID: 11489798.
18. Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Classification and regression tree analysis of 1000 consecutive patients with unknown primary carcinoma. Clin Cancer Res 5(11):3403-10, 1999. PMID: 10589751.
19. Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordoñez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?. J Clin Oncol 15(5):2056-66, 1997. PMID: 9164218.
20. Lenzi R, Frost P, Abbruzzese JL. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res 14(1A):247-51, 1994. PMID: 7513143.
21. Lenzi R, Raber MN, Frost P, Schmidt S, Abbruzzese JL. Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin. Eur J Cancer 29A(11):1634, 1993. PMID: 8217373.
22. Lenzi R, Liu MH, Lenzen R, Han T, Alpini G, Tavoloni N. Distribution of glucose-6-phosphatase activity in normal, hyperplastic, and preneoplastic rat liver. Virchows Arch B Cell Pathol Incl Mol Pathol 61(4):279-87, 1991. PMID: 1685820.
23. Alpini G, Lenzi R, Zhai WR, Liu MH, Slott PA, Paronetto F, Tavoloni N. Isolation of a nonparenchymal liver cell fraction enriched in cells with biliary epithelial phenotypes. Gastroenterology 97(5):1248-60, 1989. PMID: 2477298.
24. Alpini G, Lenzi R, Sarkozi L, Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest 81(2):569-78, 1988. PMID: 2448343.
25. Alpini G, Lenzi R, Brownell M, Tovoloni N. Isolation and characterazatiion of biliary epithelial cells from rats with bile ductular cell hyperplasia. Hepatology(6):349, 1986.

Book Chapters

1. Lenzi R. Unknown primary carcinoma. In: Primary Care: A Collaborative Practice. 4th. Mosby Inc., Affiliate of Elsevier Inc, 2013.
2. Glover KY, Varadhachary GR, Lenzi R, Raber MN, Abbruzzese JL. Carcinoma of unknown primary. In: Abeloff's Clinical Oncology. 4th. Churchill Livingstone: Philadelphia, Pennsylvania, 2057-2074, 2008.
3. Lenzi R. Unknown primary carcinoma. In: Primary Care: A Collaborative Practice. 3rd. Mosby: St. Louis, Missouri, 1349-1352, 2008.
4. Varadhachary GR, Lenzi R. Radiographic studies, endoscopy, and serum tumor markers in the diagnostic evaluation of carcinomas of unknown primary site. In: Carcinoma of Unknown Primary Site. Taylor and Francis Group: New York, New York, 11-22, 2006.
5. Lenzi R, Culine S. Prognostic considerations in patients with unknown primary carcinoma. In: Carcinoma of Unknown Primary Site. Taylor and Francis Group: New York, New York, 61-75, 2006.
6. Lenzi R, Baile WF, Rodary C, Parker PA. Psychosocial aspects of cancer of unknown primary site. In: Carcinoma of Unknown Primary Site. Taylor and Francis Group: New York, New York, 175-190, 2006.
7. Lenzi R. Unknown Primary Carcinoma. In: Primary Care: A Collaborative Practice. Mosby, Inc, Affiliate of Elsevier Inc, 2005.
8. Weinberg JS, Lenzi R, Gokaslan ZL. Brain metastasis from upper gastrointestinal tract cancers: esophageal, gastric, hepatic, gallbladder, and pancreatic. In: Intracranial Metastases: Current Managment Strategies. Blackwell Futura: Malden, MA, 362-80, 2004.
9. Lenzi R. Unknown primary carcinoma. In: Primary Care: A Collaborative Practice. 5th. Mosby Inc., Affiliate of Elsevier Inc.